Advances in Radiation Oncology (Sep 2021)

Outpatient ocular brachytherapy: The USC Experience

  • Sarah Joh, BS,
  • Mary E. Kim, BA,
  • Michael Reilly, PhD,
  • Sue Y. Zhou, MS,
  • Jonathan Kim, MD,
  • Richard L. Jennelle, MD,
  • Jesse L. Berry, MD

Journal volume & issue
Vol. 6, no. 5
p. 100737

Abstract

Read online

Purpose: Ocular brachytherapy is a standard-of-care surgical procedure for globe salvage in the treatment of uveal melanoma. The procedure involves the placement and subsequent removal of a radioactive plaque several days later. At many locations, patients are admitted on an inpatient basis until plaque removal due to radiation safety concerns. However, patients may be discharged to home after plaque insertion, and subsequently return to the medical facility for plaque removal. This study aimed to evaluate the safety and systematic financial benefit of the outpatient ocular brachytherapy program at ''?>the University of Southern California (USC) Roski Eye Institute for 30 years. Methods and Materials: A single-institution retrospective record review was performed on all 275 patients who underwent brachytherapy for ocular tumors between January 1, 1989 and December 31, 2019 to assess for occurrences of reportable radiation and/or patients safety events. The treatment protocols at our institution are described. Data on hospital-adjusted expenses per inpatient day from the American Hospital Association's 2018 Annual Survey were used as a proxy for costs to patients and the health care system to perform a cost–benefit analysis comparing outpatient versus inpatient brachytherapy. Results: Of the 275 plaque procedures over a 30-year period that were reviewed, there were no internally or externally reportable patient or radiation safety events. There were no adverse events related to patient transportation to the hospital, the patient not returning for plaque removal, operative issues in removing the plaque on time due to cancelled or delayed cases, or loss of radioactive material. Additionally, our cost–benefit analysis estimates that outpatient brachytherapy reduced costs for USC’s patients in 2018 by an average of $24,722 per patient treated with ocular brachytherapy. Conclusions: With appropriate measures, outpatient ocular brachytherapy allows patients to safely return home with the added benefit of decreased financial burden for both patients and the broader health care system.